Get Premium to unlock powerful stock data
Glaukos Corp logo

Glaukos Corp

$ 41.60 +0.95 (+2.34%) 10:08 PM EST
P/E:
At Loss
P/B:
3.29
Market Cap:
$ 1.97B
Enterprise V:
$ 1.94B
Volume:
218.14K
Avg Vol (2M):
549.13K
Also Trade In:
Volume:
218.14K
Market Cap $:
1.97B
PE Ratio:
At Loss
Avg Vol (2-Month):
549.13K
Enterprise Value $:
1.94B
PB Ratio:
3.29
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Glaukos Corp () from 2015 to May 29 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Glaukos stock (GKOS) PE ratio as of May 29 2022 is 0. More Details

Glaukos PE Ratio (TTM) Chart

EMBED

Glaukos PE Ratio (TTM) Historical Data

Total 1248
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Glaukos PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-05-29At Loss 2022-03-28At Loss
2022-05-27At Loss 2022-03-25At Loss
2022-05-26At Loss 2022-03-24At Loss
2022-05-25At Loss 2022-03-23At Loss
2022-05-24At Loss 2022-03-22At Loss
2022-05-23At Loss 2022-03-21At Loss
2022-05-20At Loss 2022-03-18At Loss
2022-05-19At Loss 2022-03-17At Loss
2022-05-18At Loss 2022-03-16At Loss
2022-05-17At Loss 2022-03-15At Loss
2022-05-16At Loss 2022-03-14At Loss
2022-05-13At Loss 2022-03-11At Loss
2022-05-12At Loss 2022-03-10At Loss
2022-05-11At Loss 2022-03-09At Loss
2022-05-10At Loss 2022-03-08At Loss
2022-05-09At Loss 2022-03-07At Loss
2022-05-06At Loss 2022-03-04At Loss
2022-05-05At Loss 2022-03-03At Loss
2022-05-04At Loss 2022-03-02At Loss
2022-05-03At Loss 2022-03-01At Loss
2022-05-02At Loss 2022-02-28At Loss
2022-04-29At Loss 2022-02-25At Loss
2022-04-28At Loss 2022-02-24At Loss
2022-04-27At Loss 2022-02-23At Loss
2022-04-26At Loss 2022-02-22At Loss
2022-04-25At Loss 2022-02-21At Loss
2022-04-22At Loss 2022-02-18At Loss
2022-04-21At Loss 2022-02-17At Loss
2022-04-20At Loss 2022-02-16At Loss
2022-04-19At Loss 2022-02-15At Loss
2022-04-18At Loss 2022-02-14At Loss
2022-04-15At Loss 2022-02-11At Loss
2022-04-14At Loss 2022-02-10At Loss
2022-04-13At Loss 2022-02-09At Loss
2022-04-12At Loss 2022-02-08At Loss
2022-04-11At Loss 2022-02-07At Loss
2022-04-08At Loss 2022-02-04At Loss
2022-04-07At Loss 2022-02-03At Loss
2022-04-06At Loss 2022-02-02At Loss
2022-04-05At Loss 2022-02-01At Loss
2022-04-04At Loss 2022-01-31At Loss
2022-04-01At Loss 2022-01-28At Loss
2022-03-31At Loss 2022-01-27At Loss
2022-03-30At Loss 2022-01-26At Loss
2022-03-29At Loss 2022-01-25At Loss

Glaukos PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Glaukos Corp logo

Business Description

Industry
Healthcare » Medical Devices & Instruments » NAICS : 339112 SIC : 3845
Traded in other countries / regions
Address
229 Avenida Fabricante, San Clemente, CA, USA, 92672
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.